HLS Therapeutics (TSE:HLS) Shares Down 0.2% - Time to Sell?

HLS Therapeutics Inc. (TSE:HLS - Get Free Report) shares were down 0.2% during trading on Wednesday . The company traded as low as C$4.85 and last traded at C$4.87. Approximately 6,901 shares changed hands during mid-day trading, a decline of 49% from the average daily volume of 13,448 shares. The stock had previously closed at C$4.88.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus raised their price target on HLS Therapeutics from C$3.50 to C$4.00 and gave the stock a "hold" rating in a research note on Wednesday, March 26th.

HLS Therapeutics Stock Down 0.8%

The business has a 50-day simple moving average of C$4.81 and a two-hundred day simple moving average of C$4.37. The company has a debt-to-equity ratio of 86.50, a quick ratio of 1.01 and a current ratio of 1.56. The company has a market capitalization of C$107.46 million, a price-to-earnings ratio of -4.84 and a beta of 1.07.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.